Cancer Cytopathology (ISSN 1934-662X, 1934-6638) is a journal published by Wiley in the United States. It covers Biochemistry, Genetics and Molecular Biology, Medicine and Cancer Research. It is indexed in Scopus, Web of Science, PubMed and HEC. Recorded metrics: impact factor 2.9, Scopus Q1, Web of Science Q3, CiteScore 6.1 and HEC W-Category. Article processing charge: USD 3,310.
Subject areaBiochemistryGenetics and Molecular BiologyMedicineCancer ResearchOncology
IndexedScopusWeb of SciencePubMedHEC
About the journal© American Cancer Society LATEST ISSUE > Volume 134, Issue 12 December 2026 Cancer Cytopathology, a journal of the American Cancer Society, publishes research of interest to cytopathology, cytology, and pathology professionals as it relates to topics concerning the etiology of cancer, its diagnosis and prevention. The journal maintains an international scope and is considered the elite journal in the field of cytopathology. Journal Metrics 6.1 CiteScore 2.9 Journal Impact Factor 13% Acceptance rate 1 days Submission to first decision (median) Cancer Cytopathology Practice Essentials series To support practicing cytopathologists, trainees, and general pathologists seeking high-yield updates, Cancer Cytopathology has launched Cancer Cytopathology Practice Essentials—a growing series of concise, expert-authored reviews designed for real-world diagnostic practice. Access the series here. Articles Most Recent Most Cited Most Read CytoSource Free Articles Open access Update on the impact of volume and cellularity on serous fluids: Nondiagnostic definitions and criteria for the upcoming International System v2 Kaitlin E. Sundling MD, PhD, Miguel A. Perez-Machado, Mauro Saieg MD, PhD, FIAC, First Published: 18 November 2026 Abstract The International System for Reporting Serous Effusions 1.0 sought to establish diagnostic criteria and terminology, including for nondiagnostic (ND) effusions. This review aims to provide a timely update to the literature on ND effusions, including addressing recommended specimen volumes, ND rate, and risk of malignancy. Abstract Full text ePub PDF References Request permissions Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing Neha Khaitan MD, Jaleh Esmaeeli MD, Anita Zamanigohar BSc, Paria Sokhanran BSc, Yung-Fang Tu MD, MSc, Khashayar Saybani MD, Lara Maria Stričak MD, Aland Barzinjy, Karolina Oscilowicz MD, Ghazal Sokhanran BMLSc, Christopher C. Griffith MD, PhD, Reza Alaghehbandan MD, MSc, FRCPC, FACE, FIAC, First Published: 18 November 2026 Abstract In this molecular–testing-free, population-based cohort of 611 atypia of undetermined significance thyroid nodules, a benign repeat fine-needle aspiration (FNA) obviated surgery in 88.8% of nodules and marked a minimum observed malignancy proportion of 2.6%, whereas upgraded cytology identified high-risk nodules. Cytomorphologic subclassification provided complementary risk stratification, supporting repeat FNA as a cost-effective first-line triage strategy. Abstract Full text ePub PDF References Request permissions Utilizing Afirma GRID scores to further stratify genomic sequencing classifier–suspicious thyroid nodules Taryn L. Waraksa-Deutsch DHSc, Simon Sung MD, Rajeswari Nagarathinam MD, Yulan Gong MD, Juanita R. Kcomt MD, Jobran Mansour MD, Min Huang MD, PhD, Hormoz Ehya MD, Shuanzeng Wei MD, PhD, First Published: 13 November 2026 Abstract In this study, Afirma GRID (Genomic Resource for Intelligence Discovery) data were used to investigate thyroid nodules that were identified as suspicious by the Afirma genomic sequencing classifier from patients who underwent surgery at the authors’ institution. The objective was to determine whether GRID data may provide additional insights into the risk stratification of cytologically indeterminate thyroid nodules. The GRID scores demonstrated promising clinical utility for improved risk stratification of genomic sequencing classifier–suspicious thyroid nodules. More articles free access The Pap test and Bethesda 2014 Ritu Nayar MD, David C. Wilbur MD, Pages: 271-281 First Published: 1 May 2015 Abstract The history of “The Bethesda System” for reporting cervical cytology goes back almost 3 decades. This terminology and the process that created it have had a profound impact on the practice of cervical cytology for laboratorians and clinicians alike. Herein, we summarize the process and rationale by which updates were made to the terminology in 2014 and outline the contents of the new, third edition of the Bethesda atlas and corresponding website. free access Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment Masato Nakaguro MD, PhD, Yuichiro Tada MD, PhD, William C. Faquin MD, PhD, Peter M. Sadow MD, PhD, Lori J. Wirth MD, Toshitaka Nagao MD, PhD, Pages: 693-703 First Published: 18 May 2020 Abstract Salivary duct carcinoma is the most aggressive subtype of primary salivary gland carcinoma. Recent studies have clarified the biology and clinicopathological features of this entity, in turn leading to the introduction of new therapies. free access Performance of an artificial intelligence algorithm for reporting urine cytopathology Adit B. Sanghvi MISM, Erastus Z. Allen MBA, Keith M. Callenberg PhD, Liron Pantanowitz MD, Pages: 658-666 First Published: 14 August 2019 Abstract The authors report the successful development of an image algorithm that applies computational methods to digitized liquid-based urine cytology slides. The algorithm is reported to achieve an area under the curve of 0.88, a sensitivity of 79.5%,
Aims and Scope© American Cancer Society LATEST ISSUE > Volume 134, Issue 12 December 2026 Cancer Cytopathology, a journal of the American Cancer Society, publishes research of interest to cytopathology, cytology, and pathology professionals as it relates to topics concerning the etiology of cancer, its diagnosis and prevention. The journal maintains an international scope and is considered the elite journal in the field of cytopathology. Journal Metrics 6.1 CiteScore 2.9 Journal Impact Factor 13% Acceptance rate 1 days Submission to first decision (median) Cancer Cytopathology Practice Essentials series To support practicing cytopathologists, trainees, and general pathologists seeking high-yield updates, Cancer Cytopathology has launched Cancer Cytopathology Practice Essentials—a growing series of concise, expert-authored reviews designed for real-world diagnostic practice. Access the series here. Articles Most Recent Most Cited Most Read CytoSource Free Articles Open access Update on the impact of volume and cellularity on serous fluids: Nondiagnostic definitions and criteria for the upcoming International System v2 Kaitlin E. Sundling MD, PhD, Miguel A. Perez-Machado, Mauro Saieg MD, PhD, FIAC, First Published: 18 November 2026 Abstract The International System for Reporting Serous Effusions 1.0 sought to establish diagnostic criteria and terminology, including for nondiagnostic (ND) effusions. This review aims to provide a timely update to the literature on ND effusions, including addressing recommended specimen volumes, ND rate, and risk of malignancy. Abstract Full text ePub PDF References Request permissions Repeat FNA for risk stratification of atypia of undetermined significance in thyroid nodules: A population‐based cohort without molecular testing Neha Khaitan MD, Jaleh Esmaeeli MD, Anita Zamanigohar BSc, Paria Sokhanran BSc, Yung-Fang Tu MD, MSc, Khashayar Saybani MD, Lara Maria Stričak MD, Aland Barzinjy, Karolina Oscilowicz MD, Ghazal Sokhanran BMLSc, Christopher C. Griffith MD, PhD, Reza Alaghehbandan MD, MSc, FRCPC, FACE, FIAC, First Published: 18 November 2026 Abstract In this molecular–testing-free, population-based cohort of 611 atypia of undetermined significance thyroid nodules, a benign repeat fine-needle aspiration (FNA) obviated surgery in 88.8% of nodules and marked a minimum observed malignancy proportion of 2.6%, whereas upgraded cytology identified high-risk nodules. Cytomorphologic subclassification provided complementary risk stratification, supporting repeat FNA as a cost-effective first-line triage strategy. Abstract Full text ePub PDF References Request permissions Utilizing Afirma GRID scores to further stratify genomic sequencing classifier–suspicious thyroid nodules Taryn L. Waraksa-Deutsch DHSc, Simon Sung MD, Rajeswari Nagarathinam MD, Yulan Gong MD, Juanita R. Kcomt MD, Jobran Mansour MD, Min Huang MD, PhD, Hormoz Ehya MD, Shuanzeng Wei MD, PhD, First Published: 13 November 2026 Abstract In this study, Afirma GRID (Genomic Resource for Intelligence Discovery) data were used to investigate thyroid nodules that were identified as suspicious by the Afirma genomic sequencing classifier from patients who underwent surgery at the authors’ institution. The objective was to determine whether GRID data may provide additional insights into the risk stratification of cytologically indeterminate thyroid nodules. The GRID scores demonstrated promising clinical utility for improved risk stratification of genomic sequencing classifier–suspicious thyroid nodules. More articles free access The Pap test and Bethesda 2014 Ritu Nayar MD, David C. Wilbur MD, Pages: 271-281 First Published: 1 May 2015 Abstract The history of “The Bethesda System” for reporting cervical cytology goes back almost 3 decades. This terminology and the process that created it have had a profound impact on the practice of cervical cytology for laboratorians and clinicians alike. Herein, we summarize the process and rationale by which updates were made to the terminology in 2014 and outline the contents of the new, third edition of the Bethesda atlas and corresponding website. free access Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment Masato Nakaguro MD, PhD, Yuichiro Tada MD, PhD, William C. Faquin MD, PhD, Peter M. Sadow MD, PhD, Lori J. Wirth MD, Toshitaka Nagao MD, PhD, Pages: 693-703 First Published: 18 May 2020 Abstract Salivary duct carcinoma is the most aggressive subtype of primary salivary gland carcinoma. Recent studies have clarified the biology and clinicopathological features of this entity, in turn leading to the introduction of new therapies. free access Performance of an artificial intelligence algorithm for reporting urine cytopathology Adit B. Sanghvi MISM, Erastus Z. Allen MBA, Keith M. Callenberg PhD, Liron Pantanowitz MD, Pages: 658-666 First Published: 14 August 2019 Abstract The authors report the successful development of an image algorithm that applies computational methods to digitized liquid-based urine cytology slides. The algorithm is reported to achieve an area under the curve of 0.88, a sensitivity of 79.5%,
Instructions for Authors URL—
Average Time To Publication After Submission (In Weeks)—
WoS StatusScience Citation Index Expanded (SCIE)